Clinical Trials — Skin Cancer

                                                                                            Click on trial for description and contact information.

 

A Phase I/II Open-Label, Randomized, Three-Arm, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RAF265 (CHIR-265) Administered Orally to Patients with Locally Advanced or Metastatic Melanoma

Revised September 12, 2009.  Please send comments, suggestions or questions about this page to Cancer Team, cancer@mcg.edu.